SCHEMBL30846

SCHEMBL30846

Cc1ccc(B2OC(C)(C)C(C)(C)O2)s1

nearest known ligand 0.37

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
LPL P06858 12/20 0.37
LIPG Q9Y5X9 12/20 0.37
P2RX7 Q99572 1/20 0.33
PRMT6 Q96LA8 1/20 0.32
CA1 P00915 2/20 0.32
CA2 P00918 2/20 0.32
CA9 Q16790 2/20 0.32
CA12 O43570 1/20 0.32
CA3 P07451 1/20 0.32
CA4 P22748 1/20 0.32
CA6 P23280 1/20 0.32
CA5A P35218 1/20 0.32
CA7 P43166 1/20 0.32
CA14 Q9ULX7 1/20 0.32
CA5B Q9Y2D0 1/20 0.32
MAPK1 P28482 1/20 0.32
F11 P03951 1/20 0.31
USP30 Q70CQ3 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12122390 0.89 LPL (0.35) LPLLIPGP2RX7USP30
SCHEMBL13592393 0.87 LPL (0.34) LPLLIPGUSP30
SCHEMBL120211 0.87 LPL (0.42) LPLLIPGP2RX7CA1CA2
SCHEMBL390494 0.81 LPL (0.40) LPLLIPGP2RX7CA1CA2
SCHEMBL14854211 0.78 LPL (0.36) LPLLIPGP2RX7CA1CA2
SCHEMBL2400910 0.78 LPL (0.36) LPLLIPGP2RX7CA1CA2
SCHEMBL16001682 0.78 LPL (0.36) LPLLIPGP2RX7CA1CA2
SCHEMBL5892452 0.78 LPL (0.36) LPLLIPGP2RX7CA1CA2
SCHEMBL14332445 0.78 LPL (0.43) LPLLIPGP2RX7CA1CA2
SCHEMBL16243900 0.76

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 270 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12577243-B2 Monoacylglycerol lipase modulators JANSSEN PHARMACEUTICA NV (BE) 2026-03-17 US disclosed
EP-3856178-B1 MONOACYLGLYCEROL LIPASE MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2026-03-11 EP disclosed
EP-4667458-A1 PHARMACEUTICAL COMPOSITION FOR TREATMENT OF CANCER, COMPRISING SOS1 INHIBITOR AND ANTICANCER DRUG Kanaph Therapeutics Inc. (KR) 2025-12-24 EP disclosed
US-20250333405-A1 ANTAGONISTS OF GPR39 PROTEIN VASOCARDEA INC (US) 2025-10-30 US disclosed
EP-3954685-B1 SMALL MOLECULE INHIBITORS OF LACTATE DEHYDROGENASE AND METHODS OF USE THEREOF US HEALTH (US) 2025-08-27 EP disclosed
US-12365653-B2 Small molecule inhibitors of lactate dehydrogenase and methods of use thereof THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVIC (US) 2025-07-22 US disclosed
US-20250136570-A1 HDAC INHIBITORS AND THERAPEUTIC USE THEREOF TANGO THERAPEUTICS, INC. 2025-05-01 US disclosed
CN-119661537-A Nucleoside compound, preparation method thereof, composition thereof and application of nucleoside compound in medicine 中国科学院上海药物研究所 2025-03-21 CN disclosed
US-20240400518-A1 SOS1 INHIBITOR AND USE THEREOF CYRUS THERAPEUTICS INC. (KR) 2024-12-05 US disclosed
US-20240368087-A1 SMALL MOLECULE INHIBITORS OF LACTATE DEHYDROGENASE AND METHODS OF USE THEREOF THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA 2024-11-07 US disclosed
US-20100010224-A1 PROCESS FOR PRODUCTION OF HETEROARYL-TYPE BORON COMPOUNDS WITH IRIDIUM CATALYST MITSUBISHI RAYON CO., LTD. (JP) 2010-01-14 US disclosed
US-7612218-B2 Process for production of heteroaryl-type boron compounds with iridium catalyst MITSUBISHI RAYON CO., LTD. (JP) 2009-11-03 US disclosed
US-7612218-B2 Process for production of heteroaryl-type boron compounds with iridium catalyst MITSUBISHI RAYON CO., LTD. (JP) 2009-11-03 US disclosed
US-7612218-B2 Process for production of heteroaryl-type boron compounds with iridium catalyst MITSUBISHI RAYON CO., LTD. (JP) 2009-11-03 US disclosed
US-20090186912-A1 ANTI-INFECTIVE AGENTS AND USES THEREOF ABBOTT LABORATORIES (US) 2009-07-23 US disclosed
US-20090166590-A1 FUSED THIOPHENE ACENES AND ORGANIC SEMICONDUCTORS MADE THEREFROM E. I. DU PONT DE NEMOURS AND COMPANY (US) 2009-07-02 US disclosed
WO-2009039134-A1 ANTI-INFECTIVE PYRIMIDINES AND USES THEREOF ABBOTT LABORATORIES (US) 2009-03-26 WO disclosed
WO-2009039127-A1 URACIL OR THYMINE DERIVATIVE FOR TREATING HEPATITIS C ABBOTT LABORATORIES (US) 2009-03-26 WO disclosed
US-20050148775-A1 Process for production of heteroaryl-type boron compounds with iridium catalyst MITSUBISHI RAYON CO., LTD. (JP) 2005-07-07 US disclosed
EP-1481978-A1 PROCESS FOR PRODUCTION OF HETEROARYL-TYPE BORON COMPOUNDS WITH IRIDIUM CATALYST Mitsubishi Rayon Co., Ltd. (JP) 2004-12-01 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100010224-A1 PROCESS FOR PRODUCTION OF HETEROARYL-TYPE BORON COMPOUNDS WITH IRIDIUM CATALYST PIN4, IPO5, HLCS LPL 2994/4885LIPG 4113/4885P2RX7 854/4885
US-20050148775-A1 Process for production of heteroaryl-type boron compounds with iridium catalyst PIN4, IPO5, HLCS LPL 2994/4885LIPG 4113/4885P2RX7 854/4885
US-12577243-B2 Monoacylglycerol lipase modulators MGLL, LPL, FAAH LPL 2/4885LIPG 17/4885P2RX7 1686/4885
US-20250136570-A1 HDAC INHIBITORS AND THERAPEUTIC USE THEREOF HDAC1, HDAC7, HDAC5 LPL 1410/4885LIPG 2160/4885P2RX7 4773/4885
US-12365653-B2 Small molecule inhibitors of lactate dehydrogenase and methods of use thereof LDHB, LDHA, PDHA1 LPL 969/4885LIPG 1356/4885P2RX7 4006/4885
US-20240368087-A1 SMALL MOLECULE INHIBITORS OF LACTATE DEHYDROGENASE AND METHODS OF USE THEREOF LDHB, LDHA, PDHA1 LPL 969/4885LIPG 1356/4885P2RX7 4006/4885
US-20240400518-A1 SOS1 INHIBITOR AND USE THEREOF SOS1, RAC1, SOS2 LPL 4877/4885LIPG 4523/4885P2RX7 3494/4885
US-20090166590-A1 FUSED THIOPHENE ACENES AND ORGANIC SEMICONDUCTORS MADE THEREFROM ACE2, ACE, DDT LPL 3561/4885LIPG 3031/4885P2RX7 2385/4885
US-20090186912-A1 ANTI-INFECTIVE AGENTS AND USES THEREOF MPO, SERPINB1, ELANE LPL 1579/4885LIPG 959/4885P2RX7 1663/4885
US-20250333405-A1 ANTAGONISTS OF GPR39 PROTEIN GPR39, GPR139, GPR119 LPL 736/4885LIPG 755/4885P2RX7 476/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.